NasdaqHealth CareHealth Care FacilitiesS&P SmallCap 600
$37.00
+2.21 (+6.35%)
Close of Nov 06, 2026 · end-of-day data
ACHC 8-K filings in 2026
Every material Form 8-K Acadia Healthcare filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Acadia Healthcare reported third-quarter 2026 revenue of $895.3 million, up 5.1% from a year earlier, while net income attributable to the company fell to $34.5 million, or $0.38 per diluted share, from $0.40. The company raised its full-year 2026 guidance for adjusted EBITDA and adjusted earnings per share, but the quarter included a $13.4 million favorable benefit from a Florida supplemental payment program accrual. Shareholders see higher revenue and a higher outlook alongside lower per-share profit in the quarter.
Q3 2026 revenue was $895.3 million, up 5.1%; same-facility revenue rose 5.2%.
Net income attributable to Acadia was $34.5 million, or $0.38 per diluted share, versus $0.40 a year earlier; adjusted EPS was $0.60 versus $0.72.
Full-year 2026 adjusted EPS guidance was raised to $1.70 to $1.80 from $1.45 to $1.60; adjusted EBITDA guidance was raised to $615 to $625 million from $590 to $615 million.
Net leverage ratio was 3.9x Adjusted EBITDA as of September 30, 2026; cash and cash equivalents were $163.3 million.
Acadia Healthcare reported second-quarter 2026 results on July 28, 2026. Revenue was $865.8 million, roughly flat from a year earlier, while net income attributable to Acadia fell to $10.9 million, or $0.12 per diluted share, from $30.1 million, or $0.33, and Adjusted EBITDA dropped 26% to $149.2 million, including a $28.6 million professional and general liability reserve adjustment. The company raised the low end of its full-year 2026 ranges for revenue, Adjusted EBITDA, Adjusted EPS and operating cash flow, and lowered the top end of its capital expenditure range, which matters to shareholders because it shows weaker quarterly profit alongside a modestly higher outlook.
Revenue $865.8 million vs. $869.2 million in Q2 2025; same-facility revenue flat year over year
Net income attributable to Acadia $10.9 million, or $0.12 per diluted share, vs. $30.1 million, or $0.33, a year earlier
Full-year 2026 Adjusted EPS guidance $1.45 to $1.60, up from $1.35 to $1.60 in April; Adjusted EBITDA $590 million to $615 million vs. $580 million to $615 million
Conference call scheduled for Wednesday, July 29, 2026, at 9:00 a.m. Eastern Time
Acadia Healthcare reported first-quarter 2026 revenue of $828.8 million, up 7.6% from a year earlier, but reported and adjusted earnings per diluted share both fell. The company raised its full-year 2026 adjusted EBITDA and adjusted EPS guidance and issued second-quarter guidance, which matters to shareholders because the higher outlook is set against lower quarterly per-share earnings.
Revenue was $828.8 million, up 7.6%; same-facility revenue rose 7.3%
Reported EPS was $0.05 versus $0.09; adjusted EPS was $0.37 versus $0.40
Full-year 2026 adjusted EBITDA guidance raised to $580 to $615 million from $575 to $610 million
Full-year adjusted EPS guidance raised to $1.35 to $1.60 from $1.30 to $1.55; second-quarter revenue guidance is $835 to $850 million
Acadia Healthcare said CFO Todd Young will resign effective April 30, 2026, to take a CFO role at a private equity-backed animal health company. The board appointed former CFO David Duckworth as interim CFO effective May 1, 2026, and the company reaffirmed its first-quarter and full-year 2026 guidance, so the financial outlook is unchanged.
Todd Young resigns as CFO effective April 30, 2026, and will join the first-quarter earnings call on April 30.
David Duckworth, CFO from July 2012 to July 2023, becomes interim CFO effective May 1, 2026, and is expected to serve at least until a permanent CEO is named.
Duckworth's employment agreement sets a base salary at a monthly rate of $100,000 and a quarterly cash bonus of $125,000.
Guidance reaffirmed: full-year 2026 revenue of $3.37 to $3.45 billion and adjusted EPS of $1.30 to $1.55; first-quarter results due after the close on April 29.
Acadia Healthcare appointed Daniel Cancelmi, former Executive Vice President and Chief Financial Officer of Tenet Healthcare, as a Class III director effective March 12, 2026. Director Wade Miquelon will not stand for reelection and retires at the 2026 annual meeting, when the board returns to 10 members. The company said the appointment followed engagement with Khrom Capital and that it continues to evaluate all paths to deliver enhanced shareholder value.
Daniel Cancelmi appointed to the board effective March 12, 2026, and will serve on the Audit Committee
Wade Miquelon informed the board on March 9, 2026, of his decision to retire at the 2026 annual meeting
Board size increases from 10 to 11 now and returns to 10 when Miquelon's retirement takes effect
Cancelmi was selected after a search led by the Nominating and Corporate Governance Committee, following engagement with Khrom Capital
Acadia Healthcare reported fourth-quarter 2025 revenue of $821.5 million, up 6.1% year over year, but posted a net loss of $(13.02) per diluted share compared with net income of $0.35 a year earlier, driven by a $996.2 million non-cash goodwill impairment charge. Adjusted earnings per diluted share fell to $0.07 from $0.64, and the company also gave 2026 guidance calling for revenue of $3.37 to $3.45 billion and adjusted EBITDA of $575 to $610 million, with Debbie Osteen announced as chief executive officer.
Q4 2025 adjusted EBITDA was $99.8 million, compared with $153.1 million a year earlier, including a $52.7 million adjustment to professional and general liability reserves.
Full-year 2025 revenue was $3,312.8 million, up 5.0%, while the full-year net loss was $(12.16) per diluted share.
2026 guidance: revenue of $3.37 to $3.45 billion, adjusted EBITDA of $575 to $610 million, and adjusted earnings per diluted share of $1.30 to $1.55.
Debbie Osteen is identified as Chief Executive Officer; the conference call is scheduled for February 25, 2026 at 9:00 a.m. Eastern Time.
Acadia Healthcare's Chief Executive Officer Christopher Hunter left the role and the Board of Directors effective January 20, 2026. His separation agreement provides cash severance, a $1,785,000 retention bonus payment, and continued eligibility for 2025 bonus and prorated performance stock units, while unvested equity was forfeited.
Departure effective January 20, 2026; Hunter also resigned from the Board
Severance equal to 1.5 times base salary plus 2025 target bonus, paid over 18 months
Acadia Healthcare said Christopher H. Hunter left his role as chief executive and the Board effective January 20, 2026, and that Debra K. Osteen, a former CEO from 2018 to 2022, has been appointed CEO and a Class I director. The company also reaffirmed its 2025 financial guidance, leaving revenue, Adjusted EBITDA and adjusted earnings per share outlook unchanged, and said the Board is conducting a search for a long-term successor.
Osteen's employment agreement sets a base salary of $1,061,000 and a target bonus of 125% of base salary.
Osteen received a stock option on 1,125,000 shares, with 750,000 shares in Tranche 1 vesting only if the 30-day VWAP reaches $25.00, $35.00 and $45.00.
2025 guidance reaffirmed: revenue of $3.28 billion to $3.30 billion, Adjusted EBITDA of $601 million to $611 million, and adjusted EPS of $1.94 to $2.04.
Hunter is expected to enter a separation and release agreement; its material terms will be disclosed in a later Form 8-K, and no terms were given in this filing.
Acadia Healthcare said it is reaffirming its 2025 financial guidance, first set in its November 5, 2025 earnings release and updated by a December 2, 2025 press release, in connection with its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The filing contains no new 2025 results and no change to the guidance ranges, so it gives shareholders a reconfirmation of the company's existing outlook.
Revenue guidance reaffirmed at $3.28 billion to $3.30 billion for 2025.
Adjusted EBITDA guidance reaffirmed at $601 million to $611 million for 2025.
Adjusted earnings per share guidance reaffirmed at $1.94 to $2.04 for 2025.
Live webcast of the presentation starts at 5:15 p.m. Pacific Time on January 13, 2026, with a replay available for thirty days.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Acadia Healthcare filing is on SEC EDGAR ↗. 8-K briefs of other companies →